^
Association details:
| Biomarker: | EGFR G719A + EGFR I706T |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Vizimpro (dacomitinib) (pan-HER inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Dacomitinib induces objective responses in metastatic brain lesions of patients with EGFR-mutant non-small-cell lung cancer: A brief report
Published date:
12/09/2020
Excerpt:
In total, 14 of 59 EGFR-mutant advanced NSCLC patients who received first-line dacomitinib therapy had brain metastasis before treatment….Eight patients harbored EGFR 19del, 5 had EGFR L858R, and one patient had EGFR G719A and I706 T co-mutations….The ORR was 92.9 % (13/14) and the disease control rate (DCR) was 100 %.
DOI:
10.1016/j.lungcan.2020.12.008
